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Abstract
Background: Successful implementation of clinical pharmacy services is associated with improvement of appropriateness
of prescribing. Both high clinical significance of pharmacist interventions and their high acceptance rate mean
that potential harm to patients could be avoided. Evidence shows that low acceptance rate of pharmacist interventions
can be associated with lack of communication between pharmacists and the rest of the healthcare team. The objective
of this study was to evaluate the effect of a structured communication strategy on acceptance rate of interventions
made by a clinical pharmacist implementing a ward-based clinical pharmacy service targeting elderly patients at high
risk of drug-related problems. Characteristics of interventions made to improve appropriateness of prescribing, their
clinical significance and intervention acceptance rate by doctors were recorded.
Methods: A clinical pharmacy intervention study was conducted between September 2013 and December 2013 in an
internal medicine ward of a teaching hospital. A trained clinical pharmacist provided pharmaceutical care to 94 patients
aged over 70 years. The clinical pharmacist used the following communication and marketing tools to implement the
service described: Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis; Specific, Measurable, Achievable,
Realistic and Timely (SMART) goals; Awareness, Interest, Desire, Action (AIDA) model.
Results: A total of 740 interventions were made by the clinical pharmacist. The most common drug classes
involved in interventions were: antibacterials for systemic use (11.1%) and anti-parkinson drugs (10.8%). The main drug-
related problem categories triggering interventions were: no specific problem (15.9%) and prescription writing error
(12.0%). A total of 93.2% of interventions were fully accepted by physicians. After assessment by an external panel 63.
2% of interventions (96 interventions/ per month) were considered of moderate clinical significance and 23.4% (36
interventions/ per month) of major clinical significance. The most frequent interventions were to educate a healthcare
professional (20.4%) and change dose (16.1%).
Conclusions: To our knowledge this is the first study evaluating the effect of a structured communication strategy on
acceptance rate of pharmacist interventions. Pharmaceutical care delivered by the clinical pharmacist is likely to have
had beneficial outcomes. Clinical pharmacy services like the one described should be implemented widely to increase
patient safety.
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Background
Clinical pharmacy is a health science discipline in which
pharmacists provide patient care that optimizes medica-
tion therapy and promotes health, wellness, and disease
prevention [1]. Clinical pharmacy services developed at
the end of 1960 in the United Kingdom and United
States of America [2, 3] and they are now playing an im-
portant role in hospitals aiming to reduce medication er-
rors and Adverse Drug Reactions (ADRs).
Appropriateness of prescribing is defined as the out-
come of a process of decision-making that maximises
net individual health gains within society’s available re-
sources [4]. Inappropriate medication prescribing in the
elderly is rising because of increase of ageing population,
number of chronic conditions and number of drugs pre-
scribed. A cohort study has found that 25.8% of elderly
receive at least one potentially inappropriate medication
[5]. Previous evidence has shown that drug histories
taken at admission by a clinical pharmacist and partici-
pation of a clinical pharmacist in medical rounds reduce
medication errors respectively by 51% and 29% [6]. It
has also been shown that clinical pharmacists participat-
ing in medical rounds and taking drug histories at ad-
mission reduce the number of ADRs [7]. Reduction in
medication errors and ADRs following the introduction
of clinical pharmacists in hospitals has been shown to
have a positive impact on reducing length of hospital
stay and mortality rate [8].
A meta-analysis looking at the association of medica-
tion use and falling found that the use of sedatives,
hypnotics, antidepressants and benzodiazepines had a
significant association with falls in elderly patients [9].
Input of the clinical pharmacist in providing information
for drug changes that might reduce fall risk has been
shown to reduce falls by up to 70% [10, 11].
Acceptance rate of interventions made by clinical phar-
macists is key as only those interventions accepted by the
healthcare team will have an impact on patient care and
might produce cost savings. Ward pharmacy services with
a high acceptance rate of interventions made by clinical
pharmacists are deemed to be cost-effective by policy-
makers. However, evidence shows that acceptance rate of
clinical pharmacist interventions can be as low as 53%
[12]. Assuming pharmacists with appropriate training and
knowledge of pharmacotherapy are employed at ward
level a possible cause for the low acceptance rate of
pharmacist interventions is lack of communication be-
tween the pharmacist and the medical team [12].
There is an assumption that if pharmacists provide
evidence base advice on medications, doctors, in turn,
will implement them. However, this is not always the
case and there is a need to foster active collaboration be-
tween the two professions applying models of communi-
cation from areas outside healthcare [13].
Several studies report on the introduction of ward based
clinical pharmacy services with a satisfactory (> 80%) ac-
ceptance rate of interventions made by clinical pharma-
cists [14–17]. However, description of the reason behind
the high acceptance rate of interventions is not reported.
Given there is no evidence on strategies adopted to
enhance acceptance rate of interventions made by ward
based clinical pharmacists the aim of the study was to
assess the effect of a tailored communication strategy on
the acceptance rate of interventions made by a clinical
pharmacist implementing a ward based clinical phar-
macy service targeting patients at high risk of drug-
related problems. Characteristics of interventions made
are described, their clinical importance is assessed and
acceptance rate by doctors is measured.
Methods
Setting and patients
The study took place between September 2013 and
December 2013 in an acute internal medicine unit of a
1099 beds teaching hospital in Italy. The unit has 39
beds and patients admitted are mostly elderly presenting
typically with acute geriatric problems and multiple dis-
eases. The healthcare team looking after patients is made
of 5 physicians specialized in internal medicine, nurses,
healthcare assistants, 1 physiotherapist, 1 dietician, and
1 social worker.
Patients aged 70 or over admitted to the unit were
included in the study. Patients were excluded from
the study if they suffered terminal illness (life expect-
ancy < 3 months); if expected length of stay was
≤48 h; if they had been enrolled in the study during
a previous admission; and if they had been transferred
from another acute unit where they had been cared
for by internal medicine physician(s).
Communication strategy
All key stakeholders (eg. hospital management, pharma-
cists, doctors, and nurses) were informed on the Strengths,
Weaknesses, Opportunities and Threats (SWOT) of
the new clinical pharmacy service using a SWOT ana-
lysis (Table 1). A SWOT analysis is a technique used
in strategic planning to enhance understanding and
decision-making in organizations and it can be ap-
plied to healthcare organizations when introducing a
new service [18].
To prove effectiveness of the new clinical phar-
macy service implemented to stakeholders type of
interventions made was described, their acceptance
rate was measured and their clinical significance was
assessed. These goals were Specific, Measurable,
Achievable, Realistic and Timely (SMART) in order
to guide and facilitate reception of the message by
stakeholders [19].
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A marketing strategy targeting key stakeholders
according to their degree of influence and import-
ance was developed. Stakeholders’ analysis is re-
ported in Fig. 1.
Hospital managers, chief pharmacist and senior med-
ical staff were targeted with high priority as they would
allocate resources and ultimately decide whether to
introduce and expand the clinical pharmacy service as
part of standard care. Junior doctors, nurses, patients
and pharmacists had high importance as they would
provide feedback to senior staff and hospital manage-
ment. However, their influence was low as they were not
decision makers. Local PCT had high influence as they
were decision makers and were involved in allocating
resources.
A marketing plan was developed according to charac-
teristics of the new service implemented and stake-
holders (Fig. 2) with particular emphasis on Awareness,
Interest, Desire, Action (AIDA model). The AIDA model
is used in marketing to help communicate effectively
with stakeholders in a way that better responds to their
needs and desires [20].
Intervention
An intervention was defined as any recommendation
made by the clinical pharmacist to a healthcare profes-
sional, pertaining to drug therapy, which aims to improve
the quality of medication use [14]. Recommendations
were either made after a prescription was written in order
to amend it or before a prescription was written in order
to advise on most appropriate prescribing (e.g. statin post
stroke in a patient with deranged liver function tests, beta-
blocker post myocardial infarction in a patient with severe
asthma). The pharmacist covered the internal medicine
unit from Monday to Friday spending on average 7 h/day
on the unit and providing pharmaceutical care from ad-
mission to discharge [21]. The pharmacist had knowledge
in geriatric pharmacotherapy and was a trained clinical
pharmacist. The pharmacist did ward rounds with the
medical team in the morning and follow ups in the
afternoon. The main tasks performed were: medicine rec-
onciliation on admission; monitoring and optimization of
medicine prescribed during hospital stay; and medicine
reconciliation on discharge [22, 23]. Priority was given to
new patients and patients going home on the day. The
Table 1 SWOT analysis
STRENGTHS WEAKNESSES
1. Chief pharmacist and Internal Medicine consultant supporting the project. 1. Ward pharmacy service offered only Monday to Friday
with no weekend cover.
2. Decrease in medication errors, ADRs and falls enhances patient safety. 2. Night on call ward pharmacy service not provided.
3. Potential for reduction in length of hospital stay and related savings. 3. Potential concerns of doctors and nurses with regard
to clinical training of the pharmacist.
OPPORTUNITIES THREATS
1. Opportunity for the trust to introduce ward clinical pharmacy. 1. Due to the current global financial crisis, it may be
difficult to find resources to expand the service in the
short term.
2. The trust is a teaching hospital and has therefore the potential for
setting up post graduate clinical pharmacy programmes to train staff.
Fig. 1 Stakeholders analysis
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pharmacist contributed to choice of drug regimen,
provided evaluated information on pharmaceutical, thera-
peutic and toxicological aspects of drug therapy, contrib-
uted to choice of dosage, form and route of medicine, and
helped with dosage calculations [24]. A pharmaceutical
care plan was made for each new patient [23, 25]. The
pharmacist had access to patient’s medical records and
blood tests. Interpretation of drug assays continued to be
performed by the clinical pharmacology department as
per standard care. When there was an opportunity for op-
timizing therapy, the pharmacist discussed it with the pre-
scriber who could accept/ partially accept or reject the
intervention. The pharmacist answered questions about
medications asked by the healthcare team on the ward. In-
terventions could be triggered either by the pharmacist or
by a member of the healthcare team asking a question to
the pharmacist. Interventions made were usually commu-
nicated orally and recorded afterward in an intervention
form. In the event the doctor looking after the patient was
not present on the ward interventions made were commu-
nicated in writing on a pharmacist intervention note. The
note reporting the intervention advised by the pharmacist
was attached to the drug chart for the doctor to be
reviewed.
Data collection
Information recorded on the intervention form were:
underlying drug-related problem (DRP) category; drug in-
volved (Anatomical Therapeutic Chemical [ATC] code)
[26]; description of intervention; outcome; type of inter-
vention and acceptance. Description of the outcome re-
corded for each intervention reported the changes that
had occurred as a direct consequence of the intervention
on the day it was made. A DRP was defined as an event or
circumstance involving drug therapy that actually or po-
tentially interferes with desired health outcomes [27].
DRPs and types of interventions were classified using a
classification system previously described in the literature
[14]. In brief, DRPs were divided in 17 categories and drug
allergy was considered a DRP. Types of interventions were
divided in 6 categories. Prior to the start of the study a
pilot was conducted on a sample of 30 patients over a 2-
week period to assess viability and reliability of the inter-
vention form.
Clinical significance
Clinical significance of interventions was defined using a
scale, developed by Spinewine and colleagues, with 5
categories: 1) minor: no benefit or minor benefit, de-
pending on professional interpretation; 2) moderate: rec-
ommendation that brings care to a more acceptable and
appropriate level of practice or that might prevent an
adverse drug event (ADE) of moderate importance; 3)
major: intervention might prevent serious morbidity,
Fig. 2 Marketing plan *,1Clinical pharmacist role was not explained
to patients unconscious, confused or unable to understand as a
consequence of their illness
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including readmission, serious organ dysfunction, ser-
ious ADE; 4) extreme: lifesaving; and 5) deleterious:
might lead to adverse outcome [14]. Clinical significance
of interventions was assessed by an independent panel
consisting of one clinical pharmacist and one senior
physician. They were from the UK and Australia, with
expertise in geriatrics and knowledge of US guidelines
(adopted locally). The scale was piloted on a sample of
25 interventions. Written instructions from the pilot
were provided to the panel to easy the use of the scale.
Panellists had no involvement in the care of patients
included in the study. The panel reviewed only interven-
tions accepted by the healthcare team and with direct
clinical impact. Significance of each intervention was
assessed independently by each panellist. If there was no
agreement the panel met to reach consensus on the
rating.
Data analysis
Data were analysed using SPSS software (Statistical
Package for the Social Sciences, version 17.0). Character-
istics of interventions were assessed using descriptive
statistics. Level of agreement for classifying DRPs and
types of interventions was assessed during the pilot
study. The principal investigator and a clinical pharma-
cist external to the study coded 33 interventions finding
a Cohen’s kappa of 0.80 for underlying DRPs and 0.85
for types of interventions. Agreement was considered
substantial and almost perfect respectively [28].
Results
Characteristics of participants
Pharmaceutical care was provided to 94 patients. The
mean (± SD) age of patients enrolled in the study was
83.3 (± 6.9); 72% were female, 89% were community-
dwelling and 16% had ≥1 hospital admission within the
previous 6 months. The average length of hospital stay
was 8.6 (± 5.4) days. Patients were taking on a regular
basis a mean of 4.8 (± 2.0) drugs and the mean number
of daily administrations was 6.5 (± 3.3). One adminis-
tration was defined as the intake of one medicine at a
given time during the day (e.g. 1 tablet of X in the
morning or 2 tablets of Y in the evening = 1 daily ad-
ministration) [29].
Interventions by drug type
A total of 740 interventions were made in 94 patients by
the clinical pharmacist. The main drug classes (ATC
level 2) involved in interventions were antibacterials for
systemic use (J01; 11.1%), anti-parkinson drugs (N04;
10.8%), psycholeptics (N05 – including antipsychotics,
anxiolytics, hypnotics and sedatives; 10.3%) and analge-
sics (N02; 9.6%). A comprehensive list of drug classes in-
volved in interventions is shown in Table 2. Intervention
details are shown in Table 3. Of the 740 interventions
690 (93.2%) were fully accepted and 611 (82.6%) were
assessed for clinical significance by the independent
panel as considered to have an impact on clinical care.
Overall, the clinical pharmacist made 63.2% (n = 386) in-
terventions of moderate clinical importance and 23.4%
(n = 143) interventions of major clinical importance.
Type of interventions, their acceptance rate and clinical
importance are presented in details in Table 4.
Discussion
A total of 143 interventions of major clinical significance
were made over a period of 4 months by a clinical
pharmacist in an internal medicine ward. That is equiva-
lent to 35 potential major drug-related problems avoided
per month. To our knowledge, this is the first study
evaluating the effect of a structured communication
strategy on acceptance rate of pharmacist interventions.
Pharmaceutical care delivered by the clinical pharmacist
is likely to have improved appropriateness of prescribing.
The majority of interventions made in our study were
either of moderate or major clinical significance.
Both the high acceptance of the pharmacist’s interven-
tions (93.2%) and their clinical significance mean that
potential harm to patients was avoided and patients care
was improved during their stay in the hospital. Other
studies using a similar definition of intervention and
similar ways of recording them report an acceptance rate
of 76%, 88.4% and 87.8% respectively [14, 16, 17]. The
acceptance rate of interventions recorded in our study is
higher. Driving forces that have contributed for the high
Table 2 Drug classes involved in interventions (N = 740)
Drug Class (ATC level 2) Interventions n (%)
Antibacterials for systemic use (J01) 82 (11.1)
Anti-parkinson drugs (N04) 80 (10.8)
Psycholeptics (N05) 76 (10.3)
Analgesics (N02) 71 (9.6)
Drugs for acid related disorders (A02) 68 (9.2)
Drugs used in diabetes (A10) 65 (8.8)
Lipid modifying agents (C10) 60 (8.1)
Vitamins (A11) 41 (5.5)
Psychoanaleptics (N06) 38 (5.1)
Beta blocking agents (C07) 33 (4.5)
Antianemic preparations (B03) 19 (2.6)
Diuretics (C03) 18 (2.4)
Antithrombotic agents (B01) 15 (2.0)
Calcium channel blockers (C08) 10 (1.4)
Drugs for obstructive airway diseases (R03) 10 (1.4)
Cardiac therapy (C01) 6 (0.8)
Miscellaneous 48 (6.5)
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acceptance rate of interventions are: aim of the study
clearly stated and communicated to healthcare profes-
sionals, direct contact with the medical team, nurses and
patients, regular presence of the pharmacist on the ward
(0.9 full-time equivalent) and pharmacist with appropriate
training in clinical pharmacy/pharmacotherapy in the eld-
erly population.
General advice on the use of newer antidiabetics, mon-
itoring of last generation antibiotics and side effects of
psycholeptics were frequently asked to the pharmacist.
Table 3 Characteristics of interventions (N = 740)
Drug-related problem Interventions n (%) Drugs involved
No specific problem*,1 118 (15.9) antibacterials for systemic use, psycholeptics, drugs used in diabetes, diuretics
Prescription writing error 89 (12.0) beta blocking agents, anti-parkinson drugs, psycholeptics
Inappropriate follow-up 83 (11.2) drugs used in diabetes, psychoanaleptics, drugs for acid related disorders,
calcium channel blockers
Less costly alternative 74 (10.0) drugs for acid related disorders, lipid modifying agents, psycholeptics, vitamins
Error in medication history 72 (9.7) anti-parkinson drugs, analgesics, beta blocking agents, psychoanaleptics
Wrong dose 66 (8.9) cardiac therapy (digoxin), drugs used in diabetes, vitamins, beta blocking agents
Underuse 54 (7.3) antianemic preparations, lipid modifying agents
Inappropriate choice of medicine 37 (5.0) antibacterials for systemic use, antithrombotic agents, psycholeptics
Inappropriate modalities of administration*,2 36 (4.9) antibacterials for systemic use, analgesics
Drug-drug interaction 20 (2.7) Analgesics
Adverse drug reaction suspected or
confirmed*,3
16 (2.2) psycholeptics, psychoanaleptics*,4
Duplication 15 (2.0) drugs for acid related disorders, drugs for obstructive airway diseases
Inappropriate duration of therapy 12 (1.6) Vitamins
No valid indication 12 (1.6) Miscellaneous
Modalities of administration not practical
for the patient
8 (1.1) Miscellaneous
Drug-disease interaction (including allergy) 6 (0.8) Miscellaneous
Other 22 (3.0) Miscellaneous
*,1No underlying drug-related problem; i.e. the clinical pharmacist is asked a drug-related question by a physician in the absence of a drug-related problem
regarding a specific patient
*,2Modalities of administration refer to frequency of administration, time, route and formulation
*,3An adverse drug reaction was defined as a noxious and unintended reaction that occurs at drug doses used in man for prophylaxis, diagnosis or therapy, that
could not be linked to another drug-related problem
*,4Psychoanaleptics include antidepressants and anti-dementia drugs
Table 4 Type, Acceptance Rate and Clinical Significance of Interventions
Intervention Type n (%) Acceptance Rate (%) Clinical Significance (%)*,1
Full Partial*,2 Rejected Minor Moderate Major Extreme Deleterious
Educate/inform healthcare professional 151 (20.4) 96.0 2.6 1.3 NA NA NA NA NA
Change dose 119 (16.1) 94.1 3.4 2.5 1.0 73.7 24.6 1.0 0
Switch to other drug 109 (14.7) 94.5 3.7 1.8 20.2 64.2 14.7 0 0.9
Discontinue drug 105 (14.2) 89.5 6.7 3.8 16.2 59.5 21.6 2.7 0
Add a new drug 86 (11.6) 93.0 4.7 2.3 25.0 44.0 31.0 0 0
Other*,3 170 (23.0) 91.8 3.5 4.7 4.3 72.0 23.4 0 0
Total 740 (100) 93.2 3.9 2.8 12.6 63.2 23.4 0.7 0.2
NA = not applicable; i.e. clinical significance not assessed by the independent panel as intervention triggered by a healthcare professional other than the
pharmacist and/or intervention not leading to change in drug therapy
*,1N = 611 (a total of 611 interventions were assessed for clinical significance by the independent panel; panellists did not assess 129 iinterventions as considered
not to impact on clinical care)
*,2Advice accepted but partially acted upon
*,3Most common intervention types were: monitoring of medications, follow up of medications newly started, advice on form and route of administration of
medications and dosage calculations
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These advices were classified as interventions in the ab-
sence of a specific problem (15.9%), were not related to
a specific patient and were triggered by physicians
highlighting how the pharmacist was fully integrated
within the healthcare team.
Collaboration between nurses/medical staff and clin-
ical pharmacists in providing patient care is a relatively
new concept in Italy. Currently hospital pharmacists
are not ward based and their role is mainly limited to
drug dispensing with provision of limited medicine
information. This has represented a key challenge
emphasizing the need to increase awareness of the new
service implemented and build trust with the ward
team in order to promote and show potential benefits
of pharmaceutical care.
It is expected that the nature and extent of physician-
pharmacist collaboration can vary and it can be both
episodic and informal rather than as part of a continuum
of care. Research looking at interprofessional collabor-
ation between doctors and pharmacists has found that
doctors are reluctant to accept the fact that quality and
safety of medicine use can improve using the expertise
of pharmacists [13]. In our study we have overcome this
significant cultural barrier applying models of communi-
cation from the commercial world to a healthcare setting
in order to foster trust, active collaboration and team
working between the two professions with the ultimate
aim of enhancing acceptance rate of interventions.
It is expected that lack of awareness and knowledge
on the importance of ward based clinical pharmacy
services on improving appropriateness of prescribing
could be one of the reasons for rejection of pharmacist
interventions [30]. Involving all key stakeholders is key
in service implementation. The use of communication
tools such as the SWOT analysis, SMART goals and the
AIDA model are likely to have had a positive impact on
the acceptance rate of pharmacist interventions. The
SWOT analysis had the aim of explaining to doctors and
nurses the aim of the new service implemented and
forecast potential issues the team would potentially face
in future. Suggestions from stakeholders were consid-
ered when planning implementation of the service. This
in turn led to involvement of doctors and nurses from
conception of the project making them more likely to
support it.
The use of SMART goals allowed the breakdown of
the aim of the study in more simple and measurable ob-
jectives which in turn increased awareness of doctors
and nurses on the role of the clinical pharmacist at ward
level. The AIDA model helped delivering results of the
project throughout implementation of the service in a
timely and efficient way increasing involvement of
doctors and nurses. Communication was delivered, in
practice, via power point presentations on key clinical
topics tailored for the specific audience and attending
meetings to update stakeholders on progress of the
service being implemented. Information and concepts
delivered using these communication tools were then re-
inforced via email 1 week after the presentation/meeting.
Content of meetings and presentations was further
reminded to healthcare staff using face to face commu-
nication on a daily basis. A monthly email was sent to
staff summarizing key topics discussed in the last 30 days
and asking for feedback.
The average number of medication per patient on
admission was lower than reported in the literature
[14, 31]. This was due to the fact that doctors with-
hold several drugs when patients were admitted and
reintroduced them usually within the following 72 h
when the patient’s clinical picture was better defined.
The clinical pharmacist spent an important part of
his time providing ward-based teaching to healthcare
professionals. This is the reason we observed a high
number of interventions (20.4%) aiming to educate
the healthcare team. A cohort study found that 25.8% of
elderly had at least one potentially inappropriate medica-
tion prescribed [5]. Our study found that 14.2% of inter-
ventions aimed at discontinuing one or more medication
suggesting the clinical pharmacist contributed to avoid
unnecessary prescribing and generated cost savings. Cost
savings were also generated by the pharmacist advising
less costly alternative (10%) drugs. In our study it was
found that one of the main drug classes involved in inter-
ventions was psycholeptics (10.3%). The use of these drugs
is associated with falls in elderly patients [9] suggesting in-
terventions made by the clinical pharmacist in addressing
DRPs caused by psycholeptics had the potential to re-
duce falls. Our study found that 9.7% of interventions
were made to address DRPs related to errors in medi-
cation history. A US study showed that 24.2% medica-
tion history discrepancies resulted in discrepancies
during hospitalisation [32] highlighting that interven-
tions addressing medication history DRPs might have
reduced these discrepancies.
The way interventions are communicated between
doctors and pharmacists affects acceptance rates. Re-
search has shown that written communication in the
form of paper notes or entries into the medical records
result in lower acceptance rate of 39–70% [17]. High
acceptance rate of 88.4% has been reported when face-
to-face communication has been used [16]. These find-
ings are confirmed in our study where interventions
either partially accepted or rejected were communicated
attaching a pharmacist intervention note to the drug
chart and interventions accepted were communicated
and discussed with doctors orally.
To our knowledge this is the first study reporting on the
introduction of a clinical pharmacist on an acute care
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hospital ward in Italy. The trust has been accredited by
The Joint Commission (JC) as academic hospital in 2014
and benefits of the clinical pharmacy service introduced
are in line with patient safety goals required by JC [33].
Our study has provided evidence to policy makers that
a well thought and tailored communication strategy can
have a positive impact on acceptance rate of interven-
tions made by pharmacists. The ward-based clinical
pharmacy model implemented could have a significant
impact on the improvement of healthcare in hospitals.
The service could be implemented within the whole
trust using the same model and trained clinical pharma-
cists should be introduced at ward level. Pharmacoecon-
omy should be a key component in future developments
of clinical pharmacy as cost-effective quality improve-
ments are given priority within healthcare settings [8].
The main strength of the study is that clinical assess-
ment of interventions by an external independent panel
made results of the study more reliable. Furthermore the
substantial level of agreement when coding DRPs and
types of interventions highlights the extent to which the
data collected in the study are correct representations of
the variable measured. Current research shows that ward
pharmacy services like the one described can be success-
fully implemented in countries having low level of clin-
ical pharmacy input within the hospital setting using the
correct communication strategy.
The study had a number of limitations. The service
was implemented by a single clinical pharmacist on a
30 beds acute internal medicine unit. A multicentre
study was not feasible at the time due to funding issues.
The results of the study should be interpreted carefully
due to lack of generalizability. However, we believe the
clinical pharmacy model described can be replicated
elsewhere employing trained staff and the communica-
tion strategy described as we would expect other hospi-
tals have a similar operating health care system. The
study was relevant in our context as aimed at raising
awareness of hospital based clinical pharmacy services
amongst policy makers nationwide. Lack of control and
the employment of one clinical pharmacist in the study
potentially limited interpretation of results. However,
we used an external independent panel to assess inter-
ventions and findings of the study were interpreted and
discussed by the whole research team reducing the risk
of bias. Previous work has shown that clinical pharma-
cists providing pharmaceutical care to inpatients might
improve their health-related quality of life [34] however
this was not measured in our study. Persistence of
interventions after discharge was not assessed due to
lack of time. As clinical pharmacy is patient oriented,
patients’ reported experience of pharmaceutical care
should have been measured using a patient satisfaction
questionnaire.
Conclusions
We believe the communication strategy adopted has in-
creased both trust and collaboration between doctors
and the pharmacist and this has had in turn a positive
impact on acceptance rate of interventions. Pharmaceut-
ical care delivered by the clinical pharmacist is likely to
have had beneficial outcomes. Clinical pharmacy services
like the one described should be implemented widely to
increase patient safety. We reckon hospital pharmacy
stakeholders should be more proactive and invest in
ward-based clinical pharmacy services as the impact on
patient safety is likely to be immediate. Introduction of
the service is justified by the need to improve appropri-
ateness of prescribing. Clinical pharmacy services like
the one described must be evidence based and employ
staff with appropriate training.
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